{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T01:25:19Z","timestamp":1787102719069,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82100216"],"award-info":[{"award-number":["82100216"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shanghai Science and Technology Commission Yangfan Program Project","award":["21YF1406200"],"award-info":[{"award-number":["21YF1406200"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"DOI":"10.1007\/s13402-026-01241-2","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T16:26:03Z","timestamp":1781281563000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Microchromosome maintenance protein 2 is essential in immune infiltration-correlated prognosis of multiple myeloma patients by regulating cell cycle"],"prefix":"10.1007","volume":"49","author":[{"given":"Aziguli","family":"Maihemaiti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifeng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguo","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"issue":"9","key":"1241_CR1","doi-asserted-by":"publisher","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","volume":"9","author":"J Huang","year":"2022","unstructured":"J. Huang et al., The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol. 9(9), e670\u2013e677 (2022)","journal-title":"Lancet Haematol."},{"issue":"12","key":"1241_CR2","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"S.V. Rajkumar et al., International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15(12), e538\u2013e548 (2014)","journal-title":"Lancet Oncol."},{"issue":"5","key":"1241_CR3","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"A.J. Cowan et al., Diagnosis and Management of Multiple Myeloma: A Review. Jama. 327(5), 464\u2013477 (2022)","journal-title":"Jama"},{"issue":"22","key":"1241_CR4","doi-asserted-by":"publisher","first-page":"5453","DOI":"10.1158\/1078-0432.CCR-16-0868","volume":"22","author":"SK Kumar","year":"2016","unstructured":"S.K. Kumar, K.C. Anderson, Immune Therapies in Multiple Myeloma. Clin. Cancer Res. 22(22), 5453\u20135460 (2016)","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"1241_CR5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"S.L. Topalian, C.G. Drake, D.M. Pardoll, Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 27(4), 450\u2013461 (2015)","journal-title":"Cancer Cell."},{"issue":"4","key":"1241_CR6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"S.M. Ansell et al., PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl. J. Med. 372(4), 311\u2013319 (2015)","journal-title":"N Engl. J. Med."},{"issue":"4","key":"1241_CR7","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"D.M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer. 12(4), 252\u2013264 (2012)","journal-title":"Nat. Rev. Cancer"},{"issue":"23","key":"1241_CR8","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","volume":"34","author":"AM Lesokhin","year":"2016","unstructured":"A.M. Lesokhin et al., Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. J. Clin. Oncol. 34(23), 2698\u20132704 (2016)","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"1241_CR9","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1158\/1078-0432.CCR-07-4079","volume":"14","author":"R Berger","year":"2008","unstructured":"R. Berger et al., Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14(10), 3044\u20133051 (2008)","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"1241_CR10","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"P. Charoentong et al., Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. Cell. Rep. 18(1), 248\u2013262 (2017)","journal-title":"Cell. Rep."},{"key":"1241_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.canlet.2016.01.043","volume":"387","author":"T Wu","year":"2017","unstructured":"T. Wu, Y. Dai, Tumor microenvironment and therapeutic response. Cancer Lett. 387, 61\u201368 (2017)","journal-title":"Cancer Lett."},{"key":"1241_CR12","doi-asserted-by":"publisher","first-page":"1102471","DOI":"10.3389\/fimmu.2022.1102471","volume":"13","author":"C Giannotta","year":"2022","unstructured":"C. Giannotta, F. Autino, M. Massaia, The immune suppressive tumor microenvironment in multiple myeloma: The contribution of myeloid-derived suppressor cells. Front. Immunol. 13, 1102471 (2022)","journal-title":"Front. Immunol."},{"issue":"5","key":"1241_CR13","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/cncr.11618","volume":"98","author":"T Sasada","year":"2003","unstructured":"T. Sasada et al., CD4\u2009+\u2009CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer. 98(5), 1089\u20131099 (2003)","journal-title":"Cancer"},{"key":"1241_CR14","doi-asserted-by":"publisher","first-page":"1133308","DOI":"10.3389\/fimmu.2023.1133308","volume":"14","author":"C Chen","year":"2023","unstructured":"C. Chen et al., Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. Front. Immunol. 14, 1133308 (2023)","journal-title":"Front. Immunol."},{"issue":"10","key":"1241_CR15","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.2703","volume":"14","author":"TF Gajewski","year":"2013","unstructured":"T.F. Gajewski, H. Schreiber, Y.X. Fu, Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14(10), 1014\u20131022 (2013)","journal-title":"Nat. Immunol."},{"key":"1241_CR16","doi-asserted-by":"publisher","first-page":"964442","DOI":"10.3389\/fimmu.2022.964442","volume":"13","author":"Q Tang","year":"2022","unstructured":"Q. Tang et al., The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front. Immunol. 13, 964442 (2022)","journal-title":"Front. Immunol."},{"issue":"1","key":"1241_CR17","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","volume":"131","author":"ZY Xu-Monette","year":"2018","unstructured":"Z.Y. Xu-Monette, J. Zhou, K.H. Young, PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood. 131(1), 68\u201383 (2018)","journal-title":"Blood"},{"key":"1241_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"S. H\u00e4nzelmann, R. Castelo, J. Guinney, GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 14, 7 (2013)","journal-title":"BMC Bioinform."},{"key":"1241_CR19","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"P. Langfelder, S. Horvath, WGCNA: an R package for weighted correlation network analysis. BMC Bioinform. 9, 559 (2008)","journal-title":"BMC Bioinform."},{"issue":"5","key":"1241_CR20","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"G. Yu et al., clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 16(5), 284\u2013287 (2012)","journal-title":"Omics"},{"issue":"2","key":"1241_CR21","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/leu.2013.247","volume":"28","author":"WJ Chng","year":"2014","unstructured":"W.J. Chng et al., IMWG consensus on risk stratification in multiple myeloma. Leukemia. 28(2), 269\u2013277 (2014)","journal-title":"Leukemia"},{"key":"1241_CR22","doi-asserted-by":"publisher","first-page":"563666","DOI":"10.3389\/fonc.2020.563666","volume":"10","author":"Y Sun","year":"2020","unstructured":"Y. Sun et al., High Expression of Succinate Dehydrogenase Subunit A Which Is Regulated by Histone Acetylation, Acts as a Good Prognostic Factor of Multiple Myeloma Patients. Front. Oncol. 10, 563666 (2020)","journal-title":"Front. Oncol."},{"issue":"34","key":"1241_CR23","doi-asserted-by":"publisher","first-page":"5373","DOI":"10.1200\/JCO.2006.05.9584","volume":"24","author":"GJ Bates","year":"2006","unstructured":"G.J. Bates et al., Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J. Clin. Oncol. 24(34), 5373\u20135380 (2006)","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"1241_CR24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/bjc.2011.189","volume":"105","author":"MJ Gooden","year":"2011","unstructured":"M.J. Gooden et al., The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br. J. Cancer. 105(1), 93\u2013103 (2011)","journal-title":"Br. J. Cancer"},{"issue":"4","key":"1241_CR25","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/bcr1746","volume":"9","author":"DG DeNardo","year":"2007","unstructured":"D.G. DeNardo, L.M. Coussens, Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 9(4), 212 (2007)","journal-title":"Breast Cancer Res."},{"key":"1241_CR26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1146\/annurev.immunol.26.021607.090248","volume":"26","author":"J Stavnezer","year":"2008","unstructured":"J. Stavnezer, J.E. Guikema, C.E. Schrader, Mechanism and regulation of class switch recombination. Annu. Rev. Immunol. 26, 261\u2013292 (2008)","journal-title":"Annu. Rev. Immunol."},{"issue":"5","key":"1241_CR27","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"S.V. Rajkumar, Multiple, 2020 update on diagnosis, risk-stratification and management. Am. J. Hematol. 95(5), 548\u2013567 (2020)","journal-title":"Am. J. Hematol."},{"issue":"2","key":"1241_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0167-4781(98)00033-5","volume":"1398","author":"SE Kearsey","year":"1998","unstructured":"S.E. Kearsey, K. Labib, MCM proteins: evolution, properties, and role in DNA replication. Biochim. Biophys. Acta. 1398(2), 113\u2013136 (1998)","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"1241_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1128\/MMBR.68.1.109-131.2004","volume":"68","author":"SL Forsburg","year":"2004","unstructured":"S.L. Forsburg, M.C.M. Eukaryotic, proteins: beyond replication initiation. Microbiol. Mol. Biol. Rev. 68(1), 109\u2013131 (2004)","journal-title":"Microbiol. Mol. Biol. Rev."},{"issue":"12","key":"1241_CR30","doi-asserted-by":"publisher","first-page":"10354","DOI":"10.1074\/jbc.M111398200","volume":"277","author":"M Fujita","year":"2002","unstructured":"M. Fujita et al., Nuclear organization of DNA replication initiation proteins in mammalian cells. J. Biol. Chem. 277(12), 10354\u201310361 (2002)","journal-title":"J. Biol. Chem."},{"issue":"12","key":"1241_CR31","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1091\/mbc.10.12.4043","volume":"10","author":"SG Pasion","year":"1999","unstructured":"S.G. Pasion, S.L. Forsburg, Nuclear localization of Schizosaccharomyces pombe Mcm2\/Cdc19p requires MCM complex assembly. Mol. Biol. Cell. 10(12), 4043\u20134057 (1999)","journal-title":"Mol. Biol. Cell."},{"issue":"22","key":"1241_CR32","doi-asserted-by":"publisher","first-page":"4259","DOI":"10.1200\/JCO.2001.19.22.4259","volume":"19","author":"N Ramnath","year":"2001","unstructured":"N. Ramnath et al., MCM2 is an independent predictor of survival in patients with non-small-cell lung cancer. J. Clin. Oncol. 19(22), 4259\u20134266 (2001)","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"1241_CR33","first-page":"1075","volume":"8","author":"K Rodins","year":"2002","unstructured":"K. Rodins et al., Minichromosome maintenance protein 2 expression in normal kidney and renal cell carcinomas: relationship to tumor dormancy and potential clinical utility. Clin. Cancer Res. 8(4), 1075\u20131081 (2002)","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"1241_CR34","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S0962-8924(01)02203-6","volume":"12","author":"JJ Blow","year":"2002","unstructured":"J.J. Blow, B. Hodgson, Replication licensing\u2013defining the proliferative state? Trends Cell. Biol. 12(2), 72\u201378 (2002)","journal-title":"Trends Cell. Biol."},{"issue":"9","key":"1241_CR35","first-page":"2712","volume":"7","author":"MV Meng","year":"2001","unstructured":"M.V. Meng et al., Minichromosome maintenance protein 2 expression in prostate: characterization and association with outcome after therapy for cancer. Clin. Cancer Res. 7(9), 2712\u20132718 (2001)","journal-title":"Clin. Cancer Res."},{"key":"1241_CR36","doi-asserted-by":"crossref","unstructured":"L. Quan et al., Prognostic role of minichromosome maintenance family in multiple myeloma. 27(10\u201311), 819\u2013829 (2020)","DOI":"10.1038\/s41417-020-0162-2"},{"key":"1241_CR37","doi-asserted-by":"crossref","unstructured":"Y. Sun, Z. Cheng, S. Liu, MCM2 in human cancer: functions, mechanisms, and clinical significance. 28(1), 128 (2022)","DOI":"10.1186\/s10020-022-00555-9"},{"issue":"10","key":"1241_CR38","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1016\/j.molcel.2021.02.038","volume":"81","author":"W Zhang","year":"2021","unstructured":"W. Zhang et al., Targeting KDM4A epigenetically activates tumor-cell-intrinsic immunity by inducing DNA replication stress. Mol. Cell. 81(10), 2148\u20132165e9 (2021)","journal-title":"Mol. Cell."},{"key":"1241_CR39","doi-asserted-by":"crossref","unstructured":"Y. Peng et al., SKP2 inhibition activates tumor cell-intrinsic immunity by inducing DNA replication stress and genomic instability. 132(1), 81\u201392 (2025)","DOI":"10.1038\/s41416-024-02909-y"},{"issue":"3","key":"1241_CR40","first-page":"285","volume":"8","author":"C Gleason","year":"2017","unstructured":"C. Gleason, J. Kaufman, New Treatment Strategies Making an Impact in Multiple Myeloma. J. Adv. Pract. Oncol. 8(3), 285\u2013290 (2017)","journal-title":"J. Adv. Pract. Oncol."},{"key":"1241_CR41","doi-asserted-by":"crossref","unstructured":"S. Knop, M. Szarejko, N. Grz\u0105\u015bko, A phase 1b\/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma. 5(5), 940\u2013950 (2024)","DOI":"10.1002\/jha2.968"},{"issue":"17","key":"1241_CR42","doi-asserted-by":"publisher","first-page":"13366","DOI":"10.18632\/oncotarget.24351","volume":"9","author":"L Rao","year":"2018","unstructured":"L. Rao et al., Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin(\u00ae) protein MP0250: a preclinical study. Oncotarget. 9(17), 13366\u201313381 (2018)","journal-title":"Oncotarget"},{"issue":"7","key":"1241_CR43","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2352-3026(24)00105-4","volume":"11","author":"MK Khan","year":"2024","unstructured":"M.K. Khan et al., Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the USA. Lancet Haematol. 11(7), e510\u2013e520 (2024)","journal-title":"Lancet Haematol."},{"key":"1241_CR44","doi-asserted-by":"crossref","unstructured":"A. Badros et al., Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed\/refractory multiple myeloma. 130(10), 1189\u20131197 (2017)","DOI":"10.1182\/blood-2017-03-775122"},{"issue":"23","key":"1241_CR45","doi-asserted-by":"publisher","first-page":"10619","DOI":"10.7150\/thno.44871","volume":"10","author":"QF Zhang","year":"2020","unstructured":"Q.F. Zhang et al., CDK4\/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner. Theranostics. 10(23), 10619\u201310633 (2020)","journal-title":"Theranostics"}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13402-026-01241-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-026-01241-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-026-01241-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:48:01Z","timestamp":1787100481000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13402-026-01241-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["1241"],"URL":"https:\/\/doi.org\/10.1007\/s13402-026-01241-2","relation":{},"ISSN":["2211-3436"],"issn-type":[{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were approved by the Biomedical Research Ethics Committee of the Shanghai Ninth People\u2019s Hospital. The study involving patients was approved by Shanghai Ninth People\u2019s Hospital. Informed consent was obtained from all the participants in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"112"}}